PPAR gamma inhibits NF-kappa B-dependent transcriptional activation in skeletal muscle

Citation for published version (APA):


Document status and date:
Published: 01/01/2009

DOI:
10.1152/ajpendo.90632.2008

Document Version:
Publisher's PDF, also known as Version of record

Document license:
Taverne

Please check the document version of this publication:

• A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page numbers.

Link to publication

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above, please follow below link for the End User Agreement:
www.umlib.nl/taverne-license

Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.

Download date: 15 Sep. 2023
PPARγ inhibits NF-κB-dependent transcriptional activation in skeletal muscle

A. H. V. Remels,1 R. C. J. Langen,1 H. R. Gosker,1 A. P. Russell,4 F. Spaapen,3 J. W. Voncken,3
P. Schrauwen,2 and A. M. W. J. Schols1

Departments of 1Respiratory Medicine, 2Human Biology, and 3Molecular Genetics, Maastricht University, the Netherlands; and 4Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia

Submitted 26 July 2008; accepted in final form 25 April 2009

There is increasing evidence in the literature that chronic inflammatory response is causally related to skeletal muscle pathology. Wasting activation of nuclear factor (NF)-κB in skeletal muscle causes profound muscle wasting that resembles clinical cachexia, while inhibition of NF-κB signaling has proven to be sufficient to block inflammation-induced protein degradation in cultured skeletal muscle myotubes (10, 24). In type 2 diabetes mellitus (T2DM), skeletal muscle insulin resistance is associated with decreased protein abundance of the inhibitory protein of NF-κB IkBα (39) and increased transcript levels of NF-κB-dependent genes, including IL-8 in skeletal muscle (17, 27). These observations indicate that anti-inflammatory agents, capable of inhibiting NF-κB signaling, could be useful for treatment of inflammation-associated skeletal muscle abnormalities in chronic disease states.

Interestingly, it is known that activation of peroxisome proliferator-activated receptors (PPARs) can exert anti-inflammatory effects in several cell types, such as smooth muscle cells, endothelial cells, and macrophages (40, 42). PPARs are a set of nuclear receptors implicated in a multitude of physiological processes (16). They display transcriptional activity and are tissue-selectively expressed (9). To date, three PPAR subtypes have been identified: PPARα, PPARγ, and PPARδ (41). Anti-inflammatory properties of the PPARs include the potential to interfere with transcriptional pathways involved in inflammatory responses, e.g., modulation of NF-κB signaling. Several mechanisms have been described, including inhibition of IkBα degradation, reduction of RelA (p65) nuclear translocation, and diminished binding of RelA to the DNA (21, 46). Data on the potential of PPARs to interfere with NF-κB signaling in skeletal muscle, however, is lacking. Therefore, in the present study we investigated whether PPAR activation in skeletal muscle is able to modulate inflammatory mediator-induced NF-κB activity. Our results reveal that PPARγ activation suppresses cytokine-induced NF-κB transcriptional activity and target gene expression in skeletal muscle independently of nuclear translocation and DNA binding.

SUBJECTS AND METHODS

Cell culture. The murine skeletal muscle cell line C2C12 was obtained from the American Type Culture Collection (ATCC no. CRL1772; Manassas, VA). These cells are able to undergo differentiation into spontaneously contracting myotubes upon growth factor withdrawal (25). C2C12 cells were cultured as described previously (26). Cells were treated with a submaximal dose of TNF-α (1 ng/ml) or IL-1β (1 ng/ml) and/or PPAR agonists at day 6 of differentiation.

Chemicals and reagents. Tetradecylthioacetic acid (TTA) (Sigma Aldrich, Zwijndrecht, the Netherlands) was dissolved in 100% ethanol to a final concentration of 100 mM and coupled to 0.4% fatty acid-free bovine serum albumin (BSA) (Sigma Aldrich) in differentiation medium (DM) by 30’ incubation at 37°C before use. Rosiglitazone maleate (Alexis Biochemicals, Lausen, Switzerland), Wy-14643 (Biomol, Plymouth Meeting, PA, USA), GW-501516 (Alexis Biochimi,
cals), and GW-1929 (Sigma Aldrich) were all dissolved in 100% dimethyl sulfoxide (DMSO) to a stock solution of 50, 5, 25, and 20 mM, respectively. TNF-α and IL-1β (both from Calbiochem, San Diego, CA) were dissolved in 0.1% BSA.

**Transfections and plasmids.** For assessment of NF-κB transcriptional activation, C2C12 cells were stably transfected with the 6×B-TK luciferase plasmid (NF-κB reporter) as described previously (26). For assessment of PPAR transcriptional activation, C2C12 cells were stably transfected with a Human CPT IB promoter (HCBP) luciferase reporter plasmid (PPAR reporter, pSG5; Stratagene, La Jolla, CA). Cells were grown to 70% confluence and transfected using Lipofectamine according to the manufacturer’s instructions (Invitrogen, Carlsbad, CA). Transfection was performed in the presence of 3.75 μg HCBP plasmid DNA and 0.25 μg of a plasmid containing the neomycin resistance gene (pSV2-Neo; Stratagene). For selection of positive clones, cells were cultured in GM containing 800 μg/ml G418 (Calbiochem). Transient transfections were all performed by Lipofectamine according to the manufacturer’s instructions (Invitrogen).

**Reporter assays.** The NF-κB- or the PPAR-sensitive reporter cell line plates were plated in 35-mm dishes and allowed to grow to 70–80% confluence. Cells were differentiated for 6 days and then treated with the various stimuli. After the appropriate incubation times, cells were washed twice with cold phosphate-buffered saline (PBS) and subsequently lysed by adding (100 μl) 1× Reporter Lysis Buffer (Promega, Madison, WI) and incubation on ice for 10 min. Cell lysates were centrifuged (13,000 g, 1 min), and supernatants were either snap-frozen and stored at −80°C for later analysis or placed on ice for immediate analysis. Luciferase activity was measured according to manufacturer’s instructions (Promega) and corrected for total protein content (Bio-Rad, Hercules, CA). For assessment of the inhibitory potential of PPAR activation on NF-κB transcriptional activation, cells from the NF-κB-sensitive reporter cell line were incubated with PPAR activators prior to the administration of the inflammatory stimulus (TNF-α or IL-1β).

**RNA isolation, cDNA synthesis, and qPCR.** Total RNA from C2C12 myotubes was extracted using the acid guanidium thiocyanate-phenol-chloroform extraction method (Ambion, Ijsel, The Netherlands). RNA concentration was determined using a spectrophotometer. One microgram of RNA per sample was reverse transcribed into cDNA using a reverse transcription and quantitative PCR (qPCR) was performed in cDNA generated from skeletal muscle biopsies using TRIzol reagent (Invitrogen, Breda, The Netherlands). One microgram of plasmid DNA was reverse transcribed into cDNA using random hexamer primers and a Stratascript enzyme (Stratagene, Amsterdam, The Netherlands). Reverse transcription and quantitative PCR (qPCR) were performed using an MX3000p thermal cycler system and Brilliant SYBR Green QPCR Master Mix (Stratagene). To control for any variations in the efficiencies of the reverse transcription and PCR, acidic ribosomal phosphoprotein PO (36B4) was used as an internal control. The number of cycles at which the best-fit line through the log linear portion of each amplification curve intersects the noise band is inversely proportional to the log copy number. This value is referred to as the critical threshold (Ct) value. ∆Ct was calculated by subtracting the Ct for 36B4 from the Ct for the gene of interest. The relative expression of the gene of interest is calculated using the expression ΔΔCt and reported as arbitrary units. All PCR runs were performed in triplicate.

**Preparation of nuclear extracts and western blot analysis.** Nuclear extracts were prepared as described previously (45). For Western blot analysis, 4× Laemmli sample buffer [0.25 M Tris-HCl, pH 6.8, 8% (wt/vol) SDS, 40% (vol/vol) glycerol, 0.4 M DTT, and 0.04% (wt/vol) bromophenol blue] was added to nuclear extracts, followed by boiling of the samples for 5 min at 100°C and storage at −20°C. Total protein was assessed using the Bio-Rad DC protein assay kit according to the manufacturer’s instructions. Fifteen μg (RelA) or 2 μg (HIS-3) of protein was loaded per lane and separated on a 10% or 12% polyacrylamide gel (Mini Protean 3 system, Bio-Rad; RelA and HIS-3 respectively), followed by transfer to a 0.45-μm nitrocellulose membrane (Bio-Rad) by electroblotting. The membrane was blocked for 1 h at room temperature in 5% (wt/vol) nonfat dry milk. Nitrocellulose blots were washed in PBS-Tween 20 (0.05%), followed by overnight incubation (4°C) with a polyclonal antibody specific for RelA (Santa Cruz Biotechnology, Santa Cruz, CA) or HIS-3 (Abcam, Cambridge, UK). After three wash steps of 20 min each, the blots were probed with a peroxidase-conjugated secondary antibody (Vector Laboratories, Bur- lingame, CA) and visualized using SuperSignal West Pico chemiluminescent substrate (Pierce Biotechnology, Rockford, IL) according to the manufacturer’s instructions.

**Electrophoretic mobility shift analysis.** DNA binding activity of NF-κB was assessed in nuclear extracts by analysis of complexes binding to an oligonucleotide containing a κB consensus sequence (Santa Cruz Biotechnology). Two micrograms of nuclear protein was used per binding reaction, and protein-DNA complexes were resolved on a 5% polyacrylamide gel in 0.25× Tris-borate-EDTA buffer at 120 V for 2 h. Gels were dried and exposed to film (X-Omat Blue XB-1; Kodak, Rochester, NY). Shifted complexes were quantified by PhosphorImager analysis (Bio-Rad). To determine the subcomposition of the complexes, supershift reactions were performed by preincubation of the nuclear extracts with an antibody specific to the RelA subunit of NF-κB (Santa cruz Biotechnology) or a negative IgG antibody.

**Chromatin immunoprecipitation assay.** After removal of the medium, 1% formaldehyde (Fisher Scientific, Pittsburgh, PA) was added to the cells for 10 min at room temperature. Cross-linking was stopped by the addition of glycine (5 min) to a final concentration of 0.125 M. Cross-linked cells were washed twice with PBS, scraped, and resuspended in SDS buffer (100 mM NaCl, 50 mM Tris·HCl, pH 8.1, 5 mM EDTA, pH 8.0, 0.02% Na3S2O3, and 0.5% SDS). Lysates were snap-frozen on dry ice. After thawing, the cells were pelleted (6 min, 500 g) at room temperature. Cells were subsequently sonicated (10 Amp, 16 cycles, 20 s on and 100 s off). Samples underwent Proteinase K and DNase treatment, and DNA was isolated using phenol-chloroform-isooamyl alcohol precipitation. Sonication efficiency was verified on a 2% agarose gel. The supernatant was precentred (20 min, 4°C) with protein A beads blocked with herring sperm. After removal of the beads by microcentrifugation (30 min, 14,000 g, room temperature), 4 μg of RelA antibody (Abcam) was added overnight at 4°C with continuous mixing. A polyclonal antibody directed against hemagglutinin was used as a control antibody (Santa Cruz Biotechnology). Antibody-protein-DNA complexes were isolated by immunoprecipitation with blocked protein A beads. Following extensive washing, bound DNA fragments were eluted and analyzed by subsequent real-time PCR. Primers were designed around the RelA binding site in the ICAM-1 promoter: forward, 5’-GATGTCTTTTCCCCGTTGAC-3’; reverse, 5’-CAGGGGATTTCCCGGAGTACA-3’.
all subjects gave their written informed consent before the start of the study. After baseline measurements, diabetic subjects received rosiglitazone (2 × 4 mg/day) for 8 wk. At the end of this 8-wk period, all measurements were repeated. Eight weeks of rosiglitazone treatment was effective in restoring insulin sensitivity in these subjects.

Collection and processing of muscle tissue. Postabsorptive muscle biopsies of the lateral part of the quadriceps femoris were obtained under local anesthesia using the needle biopsy technique. The specimens were immediately snap-frozen in liquid nitrogen and stored at −80°C until use. The frozen tissues were weighed and subsequently homogenized using a Polytron PT 1600 E (Kinematika, Littau/Luzern, Germany) for RNA extraction.

Statistical analysis. Data were analyzed according to the guidelines of Altman et al. (3), using SPSS (Statistical Package for the Social sciences; SPSS, Chicago, IL). An unpaired Student’s t-test was used for the in vitro data, and a paired nonparametric test was used for the gene expression analysis in skeletal muscle of rosiglitazone-treated diabetic patients. Data are represented as means ± SD or median ± range when appropriate for in vitro and in vivo data, respectively. A two-tailed probability value of less than 0.05 was considered to be significant.

RESULTS

NF-κB activation by inflammatory cytokines. Transcriptional activation of NF-κB was evaluated in a stable reporter cell line. To test responsiveness to inflammatory cytokines, C2C12 myotubes were stimulated with various concentrations of TNF-α for 4 h. Stimulation with TNF-α resulted in a dose-dependent increase in NF-κB transcriptional activity (Fig. 1A). To assess whether this cell line was also responsive to inflammatory stimuli other than TNF-α, a similar stimulation experiment was performed using various concentrations of IL-1β for 4 h, yielding similar results (Fig. 1B). These data demonstrate that TNF-α and IL-1β potently induce NF-κB transcriptional activity in differentiated myotubes.

Induction of PPAR transcriptional activity by specific PPAR ligands. Responsiveness of C2C12 myocytes to PPAR agonists was verified using a PPAR-sensitive promoter reporter. Administration of the general PPAR agonist TTA for 24 h to undifferentiated C2C12 myoblasts transiently transfected with a PPAR-sensitive reporter luciferase plasmid resulted in a dose-dependent increase in PPAR-dependent transcriptional activity (Fig. 2A). Treatment of C2C12 myoblasts with specific PPAR agonists (PPARα: WY-14643; PPARδ: GW-501516 or PPARγ: rosiglitazone) for 24 h also resulted in a dose-dependent increase in PPAR transcriptional activity, with a maximal induction at 50, 1, and 75 μM, respectively (data not shown). These data show that all PPAR activators used were able to induce PPAR transcriptional activity in C2C12 myoblasts. Next, a cell line containing the PPAR-sensitive reporter construct stably integrated in the genome was developed to validate the ability of the agonists to activate PPAR-dependent transcriptional activity in differentiated C2C12 myotubes. Stimulation of C2C12 myotubes with TTA (100 μM) or specific synthetic PPAR activators (WY-14643: 50 μM; GW-501516: 1 μM, or rosiglitazone: 75 μM) resulted in an induction of PPAR transcriptional activity in a time-dependent manner with maximal inductions after 48 h of incubation (Fig. 2B). These data demonstrate that all PPAR activators used in this study induce PPAR-dependent transcriptional activity in C2C12 myoblasts and myotubes.

PPARγ activation inhibits NF-κB transcriptional activation. To assess the anti-inflammatory potential of PPAR agonists in skeletal muscle, C2C12 myotubes containing the NF-κB-sensitive reporter were treated with general or specific PPAR ligands prior to exposure to proinflammatory cytokines. Pretreatment with TTA (100 μM) resulted in a time-dependent inhibition of TNF-α-induced NF-κB transcriptional activity, with a maximal inhibitory effect at 30-min preincubation time (Fig. 3).

To assess whether the three PPAR isoforms have a differential inhibitory capacity on TNF-α-induced NF-κB activation, preincubation experiments were performed with specific PPAR agonists. Preincubation with a PPARα (WY-14643, 50 μM) or a PPARδ (GW-501516, 1 μM) activator had no significant inhibitory effect on TNF-α-induced NF-κB transcriptional activity (data not shown), whereas PPARγ activation (rosiglitazone, 75 μM) resulted in a time-dependent inhibition of TNF-α-induced NF-κB transcriptional activity.

In line with the observed inhibitory effect of rosiglitazone on TNF-α-induced NF-κB transcriptional activity, rosiglitazone also inhibited IL-1β-induced NF-κB transcriptional activity in a dose- and time-dependent manner. Here, the optimal inhibitory effect was observed at 2 h preincubation with a concentration of 200 μM rosiglitazone (Fig. 5A). To confirm that rosiglitazone-mediated inhibition of cytokine-induced NF-κB transcriptional activity did occur through a PPARγ-dependent mechanism, another, structurally unrelated PPARγ agonist
Rosiglitazone for 1 h abolished the TNF-α–induced upregulation of KC and ICAM-1 mRNA levels (Fig. 6). These observations show that PPARγ activation can reduce NF-κB target gene transcript levels in skeletal muscle and demonstrate that data obtained in the NF-κB reporter are functionally relevant.

**NF-κB target genes in skeletal muscle of rosiglitazone-treated T2DM subjects.** To verify whether muscular NF-κB activity in human subjects is suppressed by PPARγ activation, we examined the effect of 8-wk rosiglitazone treatment on muscular gene expression of ICAM-1 and IL-8 in T2DM patients. Subjects’ characteristics before and after rosiglitazone treatment are summarized in table 1. No differences were observed in IL-8 mRNA expression levels (data not shown). A trend toward lower ICAM-1 mRNA expression levels was observed in skeletal muscle after rosiglitazone treatment (0.155 ± 0.0150 vs. 0.137 ± 0.006 AU, \( P = 0.074 \); Fig. 7).

**PPARγ activation does not reduce TNF-α-induced nuclear translocation or DNA binding of NF-κB.** To explore potential mechanisms by which PPARγ activation can exert its anti-inflammatory effects, we investigated TNF-α–induced NF-κB (RelA) nuclear translocation in response to preincubation with...
rosiglitazone. As shown in Fig. 8, a pronounced increase in nuclear translocation of RelA was observed after 1 h of TNF-\(\alpha\)-stimulation. However, no reduction in TNF-\(\alpha\)-induced RelA nuclear translocation was observed after preincubation with rosiglitazone. In addition to nuclear translocation assays, EMSA analyses were performed. Figure 9, A and C, show that RelA DNA binding upon stimulation with TNF-\(\alpha\) increased dramatically. Pretreatment with rosiglitazone did not reduce NF-\(\kappa\)B DNA binding in response to TNF-\(\alpha\). Analysis of the subcomposition of the retarded complexes by supershift assay in Fig. 9B revealed that the major complex induced by TNF-\(\alpha\) (top band) contained RelA. A negative control antibody was used in lane 3. ChIP assays were performed to investigate in vivo DNA binding of RelA to the ICAM-1 promoter. As indicated in Fig. 9D, stimulation of C\(_2\)C\(_12\) myotubes with TNF-\(\alpha\) potently induced binding of RelA to its binding site in the ICAM-1 promoter. Preincubation with rosiglitazone did not reduce but rather increased TNF-\(\alpha\)-induced binding of RelA to its binding site in the ICAM-1 promoter. Aggrecan was included as a non-target of RelA, and no differences were observed between the different experimental conditions (data not shown). These results indicate that TNF-\(\alpha\)-induced NF-\(\kappa\)B transcriptional activity is suppressed by PPAR\(\gamma\) activation by a mechanism downstream of RelA DNA binding.

**DISCUSSION**

The present study reveals that PPAR\(\gamma\) activation potently inhibits TNF-\(\alpha\)- and IL-1\(\beta\)-induced NF-\(\kappa\)B transcriptional activity in skeletal muscle cells. This anti-inflammatory effect of PPAR\(\gamma\) activation is not due to decreased RelA translocation to the nucleus or reduced RelA DNA binding. In addition, PPAR\(\gamma\) activation by rosiglitazone decreased transcript levels of known NF-\(\kappa\)B target genes in vitro, while a trend toward decreased basal expression of ICAM-1 was observed in skeletal muscle of rosiglitazone-treated T2DM subjects.

We used C\(_2\)C\(_12\) cells as an experimental model for skeletal muscle (25), as previous reports had demonstrated that insulin resistance (29) and atrophy (18) are induced by inflammatory stimuli in myotubes of this cell line. Moreover, it has been established that all three different PPAR proteins are present in C\(_2\)C\(_12\) cells (7). All synthetic agonists (rosiglitazone, GW-1929, WY-14643, and GW-501516) used in our study are highly specific activators of PPAR\(\gamma\), PPAR\(\alpha\), and PPAR\(\delta\), respectively.
respectively (38). We demonstrated that the PPAR activators used in this study are capable of inducing PPAR transcriptional activity in skeletal muscle myoblasts. Importantly, for all activators, this response was maintained in fully differentiated C2C12 myotubes, which has only been reported for PPARα/H9251 in one previous study (48). In addition, other work demonstrated the potential of PPAR activators to induce DNA binding of the PPARs to their responsive elements in C2C12 myotubes but did not investigate the actual transcriptional activity of these proteins in response to PPAR activators (7).

All three PPAR subtypes have been implicated in the regulation of inflammatory responses (13). In skeletal muscle, however, reports on anti-inflammatory effects of PPAR activation are rather scarce. For example, anti-inflammatory properties have previously been ascribed to the fatty acid analog TTA, but so far not in muscle (15). In the present study, we demonstrate anti-inflammatory effects of TTA in skeletal muscle cells, based on its inhibitory actions on cytokine-induced NF-κB transcriptional activity. The inhibitory effect of TTA on NF-κB transcriptional activity was transient in nature, which could be due to metabolic processing of the fatty acid analog as it can be degraded through the ω-oxidation pathway (8).

Although the PPARα and PPARδ activators we used did induce PPAR-dependent transcriptional activation, we did not observe any effect of PPARδ or PPARα activation on TNF-α-induced NF-κB activity in skeletal muscle cells. In contrast, one recent study reported an inhibitory effect of PPARδ activation on NF-κB transcriptional activity in C2C12 myotubes (47). Those authors used a different activator of PPARδ (GW-0742) compared with the PPARα activator used in this study (GW-501516), although both activators have been shown to be highly specific for PPARδ (43). In addition, the duration of TNF-α treatment was fourfold longer compared that of with our study. With respect to PPARα, anti-inflammatory potential has been investigated and demonstrated in spleen cells and smooth muscle cells but not previously in skeletal muscle (14, 34).

In contrast to PPARα and PPARδ, activation of PPARγ by rosiglitazone inhibited cytokine-induced NF-κB activity in skeletal muscle cells in the present study in a concentration range used previously in cultured skeletal muscle cells (4, 23).
addition, another study demonstrated that rosiglitazone can attenuate NF-κB-dependent ICAM-1 production in smooth muscle cells (6). To verify these in vitro observations in an appropriate and relevant clinical setting, we explored IL-8 and ICAM-1 mRNA levels in skeletal muscle of diabetic subjects who received rosiglitazone treatment as an antidiabetic therapy. ICAM-1 levels tended to be lower compared with levels prior to rosiglitazone administration but did not reach statistical significance, possibly due to a lack of statistical power. Additionally, the effective dose of rosiglitazone that reaches the muscle in the patients unfortunately was not measured; however, it is conceivable that this dose is lower than the dose made available to the cells in our in vitro experiments. Therefore, this may explain the different results obtained in patients and in vitro cultured cells. Previously, it has been shown that rosiglitazone treatment of patients with T2DM reduced circulating inflammatory markers such as C-reactive protein (CRP), metalloproteinase (MMP)-9/gelatinase B, and TNF-α (19). Our data now show that rosiglitazone treatment possibly also reduces transcript levels of NF-κB target genes in skeletal muscle, although this observation should be confirmed in a larger patient population.

The inflammation-modulating properties of the PPARs may not depend primarily on their transcriptional activity but could rather be mediated through the ability of PPARs to interfere with inflammatory signaling cascades, including NF-κB (28, 34). In concordance, GW-1929 did not induce PPAR transcriptional activity (data not shown) but did interfere with NF-κB signaling, suggestive of a transrepression mechanism of NF-κB modulation by PPARγ in skeletal muscle, as has been reported previously in other cell types (33).

Several different transrepression mechanisms have been described to be mediated by the PPARs (14, 28, 22). These include their ability to physically associate with various transcription factors (including NF-κB) and the ability to successfully compete for limiting amounts of coactivators. Since rosiglitazone pretreatment did not reduce TNF-α-induced RelA nuclear translocation or DNA binding, the mechanism by which PPARγ activation inhibits NF-κB mediated gene tran-

Table 1. Subject characteristics before and after rosiglitazone treatment after 2-wk cessation of any preexisting antidiabetic medication

<table>
<thead>
<tr>
<th></th>
<th>Before</th>
<th>After</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>61.8±3.7</td>
<td>/</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>90.2±9.1</td>
<td>90.8±10.0</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>30.2±3.3</td>
<td>30.4±3.4</td>
</tr>
<tr>
<td>Glucose, mmol/l</td>
<td>9.8±2.2</td>
<td>8.3±1.4</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>7.3±0.7</td>
<td>7.7±1.1</td>
</tr>
<tr>
<td>Si</td>
<td>0.012±0.0019</td>
<td>0.032±0.019**</td>
</tr>
<tr>
<td>g-GT, U/l</td>
<td>43.4±35</td>
<td>22.8±11.2*</td>
</tr>
</tbody>
</table>

Values are means ± SD. Si, insulin sensitivity; γ-GT, γ-glutamyltranspeptidase; HbA1c, hemoglobin A1c. *P < 0.05, **P < 0.01 after vs. before treatment.

Fig. 6. PPARγ activation reduces TNF-α-induced transcription of NF-κB target genes. C2C12 myotubes (differentiated for 6 days) were pretreated (1 h) with rosiglitazone (150 μM) followed by 24-h incubation with TNF-α (1 ng/ml). Intracellular adhesion molecule 1 (ICAM-1) and the chemokine CXCL1 (keratinocyte-derived chemokine; KC) mRNA levels were assessed and corrected for the housekeeping gene cyclophilin A. Expression levels are depicted as %TNF-α-induced transcript levels. Each condition was performed in triplicate within an experiment. Shown are means ± SD of 3 independent experiments. Significance of difference: *P < 0.001.

Since nonspecific effects of rosiglitazone have been described (12), we used the structurally unrelated agonist GW-1929 to alternatively activate PPARγ. In line with anti-inflammatory properties of rosiglitazone as a PPARγ activator, GW-1929 also potently inhibited proinflammatory cytokine-induced NF-κB activation, which suggested that this effect is indeed mediated by PPARγ. In line with our study, agonist-induced PPARγ activation was shown to repress NF-κB activation in other cell types, e.g., macrophages and T cells, in vitro (11, 36).

To assess the functional relevance of the NF-κB reporter data, we investigated the effect of PPARγ activation by rosiglitazone on the transcription of known endogenous NF-κB target genes (32). We observed that TNF-α-induced KC and, more pronounced, ICAM-1 mRNA levels were significantly attenuated by PPARγ activation in fully differentiated C2C12 myotubes. This observation is in concordance with a recent report showing downregulated ICAM-1 mRNA levels in lung epithelial cells in response to different PPARγ agonists (5). In
scription in skeletal muscle should be located downstream of DNA binding. This may include impaired recruitment of transcriptional cofactors to the NF-κB-DNA complex (28). Alternatively, removal of repressor complexes of the NF-κB transcriptional machinery may be prevented by PPARγ following its ligand-induced SUMOylation (33).

In conclusion, we show a strong inhibitory effect of agonist-mediated PPARγ activation on inflammatory mediator-in-
duced NF-κB transcriptional activity in skeletal muscle, independent of RelA nuclear translocation and DNA binding. The exact mechanism by which this occurs remains obscure but warrants further investigation, as muscle-specific inhibition of NF-κB activity may be an interesting therapeutic venue for treatment of several inflammation-associated skeletal muscle abnormalities.

**GRANTS**

The research of H. Gosker is supported by the European Union grant QLK6-CT-2002-02285. The research of P. Schrauwen is made possible by fellowships of the Royal Netherlands Academy of Arts and Sciences. R. C. J. Langen was supported by a VENI grant (VENI 916.56.112).

**REFERENCES**


